Drug Profile

Daniluromer - Edesa Biotech

Alternative Names: EB-01

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Edesa Biotech
Class Anti-inflammatories; Nonsteroidal anti-inflammatories; Skin disorder therapies
Mechanism of Action Phospholipase A2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase III Contact dermatitis

Most Recent Events

13 Dec 2024 Phase-III clinical trials in Contact dermatitis (Topical)
23 Oct 2024 Edesa Biotech plans a phase III trial for Contact dermatitis (Topical, Cream)
15 Dec 2023 Daniluromer - Edesa Biotech is available for licensing as of 15 Dec 2023. www.edesabiotech.com

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com